Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Mar;151(3):455-8.
doi: 10.1111/j.1365-2249.2007.03483.x.

Immune tolerance induction in patients with IgA anaphylactoid reactions following long-term intravenous IgG treatment

N Ahrens  1 , C Höflich, S Bombard, H Lochs, H Kiesewetter, A Salama
Affiliations

Immune tolerance induction in patients with IgA anaphylactoid reactions following long-term intravenous IgG treatment

N Ahrens et al. Clin Exp Immunol. 2008 Mar.

Abstract

To date, there is very little information regarding the pathomechanism of IgA anaphylactoid reactions and the management of affected patients. Five adult patients with common variable immunodeficiency (CVID) and a history of anaphylactic reactions due to the administration of immunoglobulin preparations were studied. The activity of anti-IgA was determined by the gel agglutination technique using IgA-coated beads. Antibodies to IgA were detected in the serum of all five patients. Initially, IgA 'depleted' intravenous (i.v.) IgG preparations were infused carefully into the patients until the activity of anti-IgA was decreased significantly or became undetectable. Subsequently, unselected i.v. IgG preparations were infused, and the activity of anti-IgA was abolished in all cases. Intravenous IgG long-term administration results in tolerance induction in patients with IgA anaphylactoid reactions. This tolerance appears to be related to antibody blockage in the circulation and an inhibition of antibody production. Most importantly, IgA appears to play an important role in the treatment of CVID. Patients with IgA anaphylactoid reactions can be treated safely with IgA containing i.v. IgG preparations following tolerance induction.

PubMed Disclaimer

References

    1. Vassallo RR. IgA anaphylactic transfusion reactions. Part I. Laboratory diagnosis, incidence, and supply of IgA-deficient products [Review] Immunohematology. 2004;20:226–33. - PubMed
    1. Sloand EM, Fox SM, Banks SM, Klein HG. Preparation of IgA-deficient platelets. Transfusion. 1990;30:322–6. - PubMed
    1. Davenport RD, Burnie KL, Barr RM. Transfusion management of patients with IgA deficiency and anti-IgA during liver transplantation. Vox Sang. 1992;63:247–50. - PubMed
    1. Sandler SG, Mallory D, Malamut D, Eckrich R. IgA anaphylactic transfusion reactions. Transfus Med Rev. 1995;9:1–8. - PubMed
    1. Win N, Hambley H, Heaton N, Williams R. Transfusion support for a patient with severe common variable immunodeficiency with anti-IgA undergoing orthotopic liver transplantation. Vox Sang. 1997;72:251. - PubMed

MeSH terms